SynCardia Systems develops artificial heart IPO

The Total Artificial Heart (TAH-t) assumes the full function of a failed human heart in patients suffering from advanced heart failure

SynCardia Systems has developed the TAH-t which has been approved by the Food and Drug Association (FDA), Health Canada and European Commission (CE).

The number of donor hearts available each year has remained flat over the past 20 years. In Europe alone, 58% of people listed for a donor heart had been waiting for a year or more.

More than 1,400 implants of the TAH-t have already been completed successfully since 2010, the longest of which lasted for nearly four years and was eventually replaced with a transplanted heart.

According to SynCardia, 79% of near-death patients who received the TAH-t were eventually bridged to an organ transplant which saved the lives of these patients. 

SynCardia also provides the Freedom portable driver, a wearable power supply for the Total Artificial Heart which allows patients to wait at home for their transplant.